128 results about "Cell Surface Antigens" patented technology

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.

The present invention provides a combination of (i) an immune checkpoint modulator and (ii) a T-cell redirecting multifunctional antibody, or an antigen binding fragment thereof, for use in therapeutic treatment of a cancer disease. The T-cell redirecting multifunctional antibody comprises (a) a specificity against a T cell surface antigen; (b) a specificity against a cancer- and / or tumor-associated antigen; and (c) a binding site for human FcγRI, FcγRIIa and / or FcγRIII, wherein the antibody, or the antigen binding fragment thereof, binds with a higher affinity to human FcγRI, FcγRIIa and / or FcγRIII than to human FcγRIIb.

The invention provides an antibody for resisting CD19 on the surface of a porcine B cell or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, the invention provides an anti-porcine B cell surface CD19 antibody or an antigen binding fragment thereof, which can effectively bind to CD19 on the porcine B cell surface. The invention also provides an antibody drug conjugate containing the antibody or the antigen binding fragment thereof, and the antibody drug conjugate can be applied to screening of porcine B cells and marking of CD19 antigens on the surfaces of the porcine B cells, and has a good application prospect.

The present invention relates to a novel identified stem cell vMSC having angiogenesis characteristics, the vMSCs identified after being cultured under the culture conditions of the present invention are different from existing MSCs, are novel MSCs expressing CD141 cell surface antigens, have excellent cell expansibility, have an effect of directly forming blood vessels, have a paracrine effect of other MSCs, and are different from existing stem cells. The stem cell therapeutic agent for revascularization has a higher survival rate and a higher residual rate in tissues than conventional stem cell therapeutic agents, and can be used as a stem cell therapeutic agent for revascularization in which blood vessels are directly formed.

The invention relates to an application of a macrophage expressing an anti-uPAR chimeric antigen receptor in preparation of an anti-aging drug, and discloses a new application of the macrophage (CAR-M) expressing the anti-uPAR chimeric antigen receptor in senescence diseases, and the mechanism is that uPAR positive cells are specifically recognized and apoptosis of the uPAR positive cells is induced by targeting senescence cell surface antigen uPAR. According to the uPAR-CAR-M, a humanized anti-uPAR single-chain antibody is used as a chimeric antigen receptor recognition region, so that the chimeric antigen receptor has high specificity, and the chimeric antigen receptor is used for promoting the functions of macrophages by using a CD8 alpha transmembrane structural domain, a CD28 costimulatory molecule and a Megf10 sequence, so that a better killing effect is given to the CAR-M. The problems of inflammatory microenvironment caused by abnormal aggregation of senescence cells, chronic tissue damage and senescence-related disease treatment disorder are solved, and the application value for treating senescence-related diseases (such as osteoarthritis and the like) expressing uPAR is important.

The invention relates to agents and methods for targeted delivery of payloads to cells. The payload includes a variety of molecules such as therapeutic or diagnostic agents and, in particular, toxins, immunomodulators or radiodiagnostics. In some embodiments, the invention involves providing to a subject a compound comprising a payload moiety and at least two tags (tag conjugate) and a compound binding to the tags of the tag conjugate and a target antigen, e.g., a cell surface antigen on a target cell, (docking compound).

The invention belongs to the technical field of biology, and particularly relates to a preparation method of macaca fascicularis liver tissue single-cell suspension. The method comprises the following steps: cleaning macaca fascicularis liver tissues with a pre-cooling buffer solution, and processing into tissue fragments; mixing the tissue fragments with a digestion solution, wherein the digestion solution comprises collagenase I with the final concentration of 1 + / -0.2 mg / ml, collagenase II with the final concentration of 1 + / -0.2 mg / ml, bovine serum albumin with the final concentration of 0.04 + / -0.01% (w / v), DNase I with the final concentration of 10 + / -2 U / ml and the balance of a buffer solution; oscillating and incubating for 30 + / -10min under the conditions of 37 + / -2 DEG C and 150 + / -50rpm, and performing tissue digestion; centrifuging the digested suspension, removing the supernatant, resuspending with a buffer solution, and filtering with a cell sieve to obtain a single-cell primary suspension; and carrying out red blood cell lysis, washing and resuspension on the single-cell primary suspension to prepare the cynomolgus monkey liver tissue single-cell suspension. The method significantly improves the tissue dissociation efficiency, reduces cell adhesion and fragments, effectively protects cell surface antigen epitopes, and has the advantages of simple operation, economy and high efficiency.

The present invention provides a low pH pharmaceutical composition comprising (a) an antibody constructs comprising a first domain binding to a target cell surface antigen, a second domain binding to a second antigen and preferably a third domain, which is a specific Fc modality, (b) at least one buffer agent, (c) at least one saccharide, and (d) at least one surfactant; and wherein the pH of the pharmaceutical composition is in the range of 3.5 to 6.

The present invention relates to epitopes of leucine-rich immunoglobulin-like domain 1 (Lrig-1), an antigen present on the surface of regulatory T cells, and antibodies or antigen-binding fragments that specifically bind thereto.

The application discloses a detection method of cell surface antigens and application thereof, and relates to the detection field. The detection method of cell surface antigens comprises the following steps: mixing liposome-treated cells to be detected with capture microspheres and fluorescent microspheres, detecting the fluorescence intensity, and analyzing the expression of cell surface antigens. The surface of the capture microspheres is coated with a first antibody against a specific antigen on the surface of target cells. The surface of the fluorescent microspheres is coated with a second antibody against a target antigen on the surface of target cells. The detection method has low cost and can be used for directly quantitatively and qualitatively analyzing the expression of surface antigens of specific types of cells.

The present invention relates to agents and methods for targeted delivery of a payload to a cell. The payload comprises various molecules, such as therapeutic or diagnostic agents, in particular toxins, immunomodulators or radiodiagnostic agents. In some embodiments, the invention relates to providing a subject with a compound comprising a payload moiety and at least two tags (tag conjugates) and a compound (docking compound) that binds to the tags of the tag conjugates and a target antigen (e.g., a cell surface antigen on a target cell).

The invention provides an antibody for resisting CD19 on the surface of a porcine B cell or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, the invention provides an anti-porcine B cell surface CD19 antibody or an antigen binding fragment thereof, which can effectively bind to CD19 on the porcine B cell surface. The invention also provides an antibody drug conjugate containing the antibody or the antigen binding fragment thereof, and the antibody drug conjugate can be applied to screening of porcine B cells and marking of CD19 antigens on the surfaces of the porcine B cells, and has a good application prospect.

Disclosed herein are monospecific and bispecific antibodies that comprise a ALPPL2 / ALPP-binding variable region. The bi-specific antibody is comprises of a monoclonal antibody targeting a tumor-specific cell surface antigen (ALPPL2 / ALPP) with exquisite tissue specificity and a monoclonal antibody targeting a cell surface molecule (e.g., CD3) expressed by immune effector cells.

The invention relates to the technical field of biology, in particular to an anti-BAFF-R and anti-CD3 bispecific antibody and application thereof. The bispecific antibody disclosed by the invention can be specifically combined with a cell surface B cell activating factor receptor (BAFF-R) and an immune cell surface antigen molecular cluster 3 (CD3); wherein the anti-BAFF-R antibody is a full human source single domain antibody. The invention also provides a preparation method of the bispecific antibody with different combination configurations of 1 + 1, 2 + 1 and 2 + 2 and an in-vitro and in-vivo biological activity evaluation method. The bispecific antibody disclosed by the invention has relatively high affinity and can be used for treating BAFFR expressed tumor diseases and autoimmune diseases.

The present disclosure provides a low pH pharmaceutical composition comprising (a) an antibody constructs comprising a first domain binding to a target cell surface antigen, a second domain binding to a second antigen and preferably a third domain, which is a specific Fc modality, (b) at least one buffer agent, (c) at least one saccharide, and (d) at least one surfactant; and wherein the pH of the pharmaceutical composition is in the range of 3.5 to 6.

A fusion antibody and its application. The fusion antibody includes: a) IL-15; b) IL-15Ra; and c) an antibody targeting a therapeutically relevant cell surface antigen. The antibody includes a heavy chain variable region (VH), a heavy chain constant region (CH1), a light chain variable region (VL), and a light chain constant region (CL). IL-15 / IL-15Ra is located between the C-terminus of the heavy chain variable region VH and the N-terminus of the heavy chain constant region CH1, and between the C-terminus of the light chain variable region VL and the N-terminus of the light chain constant region CL. This fusion antibody prolongs its half-life and, utilizing its targeting properties, specifically reaches its target site to exert its effect, conferring IL-15 with unique cell targeting properties. It exerts its receptor activation effect only in an environment containing high receptor concentrations of IL-2βγ, thus reducing the systemic toxicity of the IL-15 / IL-15Ra complex.

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to a target cell surface antigen, a second domain binding to an extracellular epitope of the human and / or the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

The present invention relates to bispecific polypeptide molecules capable of simultaneously binding to a disease associated antigen and a cell surface antigen expressed on the surface of an immune effector cell such as a T-cell resulting in the activation of the immune effector cell.

A nanoparticle for delivery of mRNA to cell, comprising a core comprising a polyethylenimine polymer having fluorinated groups covalently coupled thereto and with mRNA reversibly associated therewith, and a shell surrounding the core comprising heparin. Ij some embodiments, the nanoparticle comprises a targeting agent associated with the shell, wherein the targeting agent is selected from the group consisting of agents that bind to receptors overexpressed on tumor cells, agents that bind to cell surf ace antigens that are expressed on pluripotent stem cells, agents that bind to cell surface antigens on T cells, and agents that bind to antigens presented by MHO molecules. Pharmaceutical compositions that include the nanoparticle and methods for using the nanoparticle for transfecting cells are provided

The present invention relates to the field of antibody technology, and more particularly to an antibody that specifically recognizes CD14 and its application in nanomagnetic bead sorting. The anti-CD14 antibody of the present invention can specifically recognize and bind to human CD14 without cross-reacting with other cell surface antigens such as CD8, CD11, CD68, CD195, etc.; the antibody has a high affinity for human CD14 and can be used as a detection antibody for CD14, and can also be used as a CD14 detection antibody. + Cell sorting antibodies achieve high purity CD14 + Efficient preparation of cells or for depletion of CD14 in CAR-T cell products + Cells can be used to improve the purity and quality of CAR-T cells, and have good application prospects in immune cell preparation and quality control.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector for specifically targeting a target cell and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen targeting artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Moreton vesicular disease virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Moreton vesicular disease virus envelope, provided by the invention, can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed based on mutated Moreton vesicular disease virus envelope protein is better in stability in serum, and has a good application prospect. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

Reported herein is a method for increasing the (avidity) binding specificity of a bispecific antibody comprising a first mammalian or mammalized binding site that specifically binds to a first (cell surface) antigen and a second binding site that specifically binds to a second (cell surface) antigen, wherein the first mammalian or mammalized binding site is at least a pair of an immunoglobulin light chain variable domain and an immunoglobulin heavy chain variable domain, by reducing the binding affinity of the mammalian or mammalized binding site to its antigen by mutating at least one amino acid residue in the first mammalian or mammalized binding site at a position located in a CDR of the light chain variable domain or in CDR1 or CDR2 of the heavy chain variable domain or in the two framework positions directly preceding CDR3 in the heavy chain variable domain to an amino acid residue that is present at said position in the germline immunoglobulin amino acid sequence of the same mammalian species as the species of the mammalian or mammalized binding site.

The present invention relates to a newly identified secretion group of vMSCs and uses thereof, different from existing MSCs, the vMSCs of the present invention obtained by culturing under specific culture conditions are novel MSCs expressing a CD141 cell surface antigen, the composition of the secretion group secreted by the vMSCs is different from that of the existing MSCs, and the secretion group significantly increases vascular budding of other stem cells, and has a significant increase in blood vessel germination rate. Therefore, the compound can be used for promoting angiogenesis of stem cells and for preventing or treating vascular diseases or vascular dysfunction.

The present invention relates to polypeptides comprising a membrane surface domain and uses thereof. In particular, the present invention provides an engineered polypeptide comprising a membrane surface domain comprising an extracellular domain of a B cell surface antigen or a variant thereof.

The invention relates to agents and methods for targeted delivery of RNA such as mRNA encoding a polypeptide comprising a cytokine ora functional variant thereof to immune cells for expression of the polypeptide. Delivering RNA encoding a cytokine to immune cells may be useful for immunomodulation of immune cells, in particular for inducing proliferation of immune cells. In some embodiments, the invention involves a particle, and a targeting compound comprising a moiety incorporating into the particle, e.g., a hydrophobic moiety, and having a binding moiety covalently attached thereto. The particle carries an RNA payload, i.e., RNA encoding a polypeptide comprising a cytokine or a functional variant thereof. Targeting of an immune cell may be achieved by the direct or indirect binding of the targeting compound to cell surface antigens on the target immune cell of interest.

The present invention provides a fusion protein for activating an immune cell to kill a tumor cell, and a recombinant virus and a use thereof. The fusion protein comprises an extracellular domain, a hinge region, a transmembrane domain, and an intracellular domain, wherein the extracellular domain is a polypeptide or an active fragment thereof that specifically binds to an immune cell surface antigen, and a killing function of the immune cell is activated by specifically binding to the immune cell surface antigen; and the transmembrane domain is a polypeptide for anchoring the fusion protein on a cell membrane of the tumor cell. The fusion protein and recombinant virus of the present invention can effectively kill the tumor cell and have broad-spectrum killing activity against various tumors.

The present invention relates to antibodies or antigen-binding fragments that specifically bind to an epitope of a Lrig-1 (leucine-rich and immunoglobulin-like domain 1) protein, said Lrig-1 protein being an antigen present on the surface of regulatory T cells. The antibody or antigen-binding fragment specifically binding to the epitope of the Lrig-1 protein according to the present invention specifically binds to the epitope of the present invention existing in regulatory T cells, thereby regulating the function of regulatory T cells, maintaining or enhancing the activity of effector T cells, and can be very effectively used in the prevention, amelioration or treatment of various diseases.

The present invention addresses the problem of providing a cell population isolated from a living body, which contains mesenchymal cells that have a prescribed cell surface antigen molecule and can be used in the production of a cell sheet. A cell population that is isolated from a living body and contains 80% or more of mesenchymal cells that express at least one type of cell surface antigen molecule selected from the group consisting of CD13, CD59, CD49e, CD151 and CD280 is used. The mesenchymal cells are preselected from cells collected from tissues in the oral cavity or a culture thereof, and preferably express at least three or more types of cell surface antigen molecules selected from the group consisting of CD13, CD59, CD49e, CD151, and CD280.

A cell processing platform and method for selective isolation and activation of target cells, such as T-cells, NK-cells, and hematopoietic stem cells, from a biological sample. The platform employs aptamer-functionalized microbubbles, which selectively bind to target cell surface antigens to create buoyant target cell-microbubble complexes. A centrifugation module separates buoyant target cells from non-target cells by exploiting their distinct buoyancy properties. The system includes advanced aptamer designs, such as Locked Nucleic Acid (LNA) modifications, temperature-controlled folding buffers, and reversible binding mechanisms using complementary strands or enzymatic cleavage to release target cells. Additional features include optimized spacer configurations to enhance binding accessibility and aptamer stability for high specificity and yield. This platform also enables selective removal of senescent cells using aptamer-functionalized microbubbles, facilitating continuous processing and supporting applications in cell therapy, research, and regenerative medicine.

A method for determining the affinity of an antibody to a cell-surface antigen. The method generally includes incubating the antibody with the cell-surface antigen and separating free antibody in solution from antibody that is bound to the cell-surface antigen. The free antibody in solution may then be added to a solid support having a fixed antigen and incubated. A labeled agent that binds to antibody that is bound to the fixed antigen is then added, and unbound label is removed. Electrochemiluminescence of the labeled agent that is bound to the antibody that is bound to the fixed antigen is then measured and that data is used to calculate a binding affinity of the antibody to the cell-surface antigen. The method may be implemented in high throughput format, may be automated and / or continuous, and further may be controlled by a central processor, for example a computer.